GDNF and Parkinson disease: Initial multi-center, double-blind clinical trials involving AAV-mediated gene therapy for PD with neurotrophic factors, such as glial-cell-derived neurotrophic factor (GDNF) (24) and neurturin (16) delivered via bilateral injections in the putamen, failed to achieve primary efficacy endpoints.